Selective Targeting of Tumor Cells in a Microfluidic Tumor Model with Multiple Cell Types.

Bas van de Crommert, Valentina Palacio-Castañeda, Wouter P R Verdurmen

Abstract read

In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Potent and selective eradication of tumor cells by an EpCAM-targeted Ras-degrading enzyme.Molecular therapy oncolytics · 2023
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Bas van de CrommertDepartment of Medical BioSciences, Radboud University Medical Center, Nijmegen, The Netherlands.

Valentina Palacio-CastañedaDepartment of Medical BioSciences, Radboud University Medical Center, Nijmegen, The Netherlands.

Wouter P R VerdurmenDepartment of Medical BioSciences, Radboud University Medical Center, Nijmegen, The Netherlands. Wouter.Verdurmen@radboudumc.nl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Organ-on-a-chip technology allows researchers to precisely monitor drug efficacy in 3D tissue culture systems that are physiologically more relevant to humans compared to 2D cultures and that allow better control over experimental conditions as compared to animal models. Specifically, the high control over microenvironmental conditions combined with the broad range of direct measurements that can be performed in these systems makes organ-on-a-chip devices a versatile tool to investigate tumor targeting and drug delivery. Here, we describe a detailed protocol for studying the cell-selective targeting of protein drugs to tumor cells on an organ-on-a-chip system using a co-culture consisting of BT-474 cancer cells and C5120 human fibroblasts as an example.

Indexed as

Coculture TechniquesLab-On-A-Chip DevicesAntineoplastic AgentsCell Line, TumorDrug Delivery SystemsFibroblastsHumansMicrofluidic Analytical TechniquesMicrofluidicsNeoplasmsTumor MicroenvironmentAntineoplastic AgentsFluorescence microscopyImage analysisOrgan-on-a-chipProtein drugTumor targeting

Identifiers

PMID38753152

DOI10.3390/bios11080292

What Socratic holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.